JAMA Network
About The Study: In a clinical trial that included 8,920 participants, a noninvasive, multitarget stool RNA test (ColoSense) for colorectal cancer screening showed high sensitivity for colorectal neoplasia (colorectal cancer and advanced adenoma) with significant improvement in sensitivity relative to the fecal immunochemical test. Specificity for no lesions on colonoscopy was comparable to existing molecular diagnostic tests.
Authors: Erica K. Barnell, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.22231)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
